{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:11:25Z","timestamp":1792008685613,"version":"4.4.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203528"],"award-info":[{"award-number":["82203528"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972559"],"award-info":[{"award-number":["81972559"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272891"],"award-info":[{"award-number":["82272891"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06093-2","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T09:40:56Z","timestamp":1737538856000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Application of adoptive cell therapy in malignant melanoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Qianrong","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangying","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangjie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanyuan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"issue":"6","key":"6093_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"6093_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"6093_CR3","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3322\/caac.21352","volume":"66","author":"MK Tripp","year":"2016","unstructured":"Tripp MK, Watson M, Balk SJ, Swetter SM, Gershenwald JE. State of the science on prevention and screening to reduce melanoma incidence and mortality: the time is now. CA Cancer J Clin. 2016;66(6):460\u201380.","journal-title":"CA Cancer J Clin"},{"issue":"21","key":"6093_CR4","doi-asserted-by":"publisher","first-page":"15881","DOI":"10.3390\/ijms242115881","volume":"24","author":"LM Gosman","year":"2023","unstructured":"Gosman LM, \u021a\u0103poi DA, Costache M. Cutaneous melanoma: a review of multifactorial pathogenesis, immunohistochemistry, and emerging biomarkers for early detection and management. Int J Mol Sci. 2023;24(21):15881.","journal-title":"Int J Mol Sci"},{"key":"6093_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103208","volume":"158","author":"S Boussios","year":"2021","unstructured":"Boussios S, Rassy E, Samartzis E, Moschetta M, Sheriff M, P\u00e9rez-Fidalgo JA, et al. Melanoma of unknown primary: new perspectives for an old story. Crit Rev Oncol Hematol. 2021;158: 103208.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10304","key":"6093_CR6","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398(10304):1002\u201314.","journal-title":"Lancet"},{"issue":"3","key":"6093_CR7","doi-asserted-by":"publisher","first-page":"1971015","DOI":"10.1080\/21645515.2021.1971015","volume":"18","author":"V Ferraresi","year":"2022","unstructured":"Ferraresi V, Vari S. Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma. Hum Vaccin Immunother. 2022;18(3):1971015.","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"6093_CR8","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","volume":"37","author":"KM Mahoney","year":"2015","unstructured":"Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1\/PD-L1 blockade in melanoma. Clin Ther. 2015;37(4):764\u201382.","journal-title":"Clin Ther"},{"issue":"1","key":"6093_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23\u201334.","journal-title":"N Engl J Med"},{"issue":"16","key":"6093_CR10","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535\u201346.","journal-title":"N Engl J Med"},{"issue":"1","key":"6093_CR11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13578-023-01073-9","volume":"13","author":"B Wang","year":"2023","unstructured":"Wang B, Han Y, Zhang Y, Zhao Q, Wang H, Wei J, et al. Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms. Cell Biosci. 2023;13(1):120.","journal-title":"Cell Biosci"},{"key":"6093_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","volume":"40","author":"MD Vesely","year":"2022","unstructured":"Vesely MD, Zhang T, Chen L. Resistance mechanisms to anti-PD cancer immunotherapy. Annu Rev Immunol. 2022;40:45\u201374. https:\/\/doi.org\/10.1146\/annurev-immunol-070621-030155.","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"6093_CR13","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.3390\/diagnostics11081341","volume":"11","author":"A Revythis","year":"2021","unstructured":"Revythis A, Shah S, Kutka M, Moschetta M, Ozturk MA, Pappas-Gogos G, et al. Unraveling the wide spectrum of melanoma biomarkers. Diagnostics. 2021;11(8):1341.","journal-title":"Diagnostics"},{"issue":"1","key":"6093_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature13121","volume":"508","author":"C Sun","year":"2014","unstructured":"Sun C, Wang L, Huang S, Heynen GJJE, Prahallad A, Robert C, et al. Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma. Nature. 2014;508(1):118\u201322.","journal-title":"Nature"},{"issue":"8","key":"6093_CR15","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/cr.2014.67","volume":"24","author":"G Zhang","year":"2014","unstructured":"Zhang G, Herlyn M. Linking SOX10 to a slow-growth resistance phenotype. Cell Res. 2014;24(8):906\u20137.","journal-title":"Cell Res"},{"key":"6093_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ejca.2016.04.005","volume":"62","author":"SJ Welsh","year":"2016","unstructured":"Welsh SJ, Rizos H, Scolyer RA, Long GV. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: where to next? Eur J Cancer. 2016;62:76\u201385.","journal-title":"Eur J Cancer"},{"issue":"3","key":"6093_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","volume":"21","author":"D Hanahan","year":"2012","unstructured":"Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309\u201322.","journal-title":"Cancer Cell"},{"key":"6093_CR18","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707\u201323.","journal-title":"Cell"},{"key":"6093_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ctrv.2016.11.007","volume":"52","author":"JS O\u2019Donnell","year":"2017","unstructured":"O\u2019Donnell JS, Long GV, Scolyer RA, Teng MWL, Smyth MJ. Resistance to PD1\/PDL1 checkpoint inhibition. Cancer Treat Rev. 2017;52:71\u201381.","journal-title":"Cancer Treat Rev"},{"key":"6093_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.coi.2021.10.004","volume":"74","author":"A Pocaterra","year":"2022","unstructured":"Pocaterra A, Catucci M, Mondino A. Adoptive T cell therapy of solid tumors: time to team up with immunogenic chemo\/radiotherapy. Curr Opin Immunol. 2022;74:53\u20139.","journal-title":"Curr Opin Immunol"},{"key":"6093_CR21","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00428-018-2484-0","volume":"474","author":"MW Rohaan","year":"2019","unstructured":"Rohaan MW, Wilgenhof S, Haanen JBAG. Adoptive cellular therapies: the current landscape. Virchows Arch. 2019;474:449\u201361.","journal-title":"Virchows Arch"},{"issue":"1","key":"6093_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000019050","volume":"15","author":"AF Kirkin","year":"1998","unstructured":"Kirkin AF, Dzhandzhugazyan K, Zeuthen J. The immunogenic properties of melanoma-associated antigens recognized by cytotoxic T lymphocytes. Exp Clin Immunogenet. 1998;15(1):19\u201332.","journal-title":"Exp Clin Immunogenet"},{"key":"6093_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.critrevonc.2017.05.001","volume":"115","author":"J Pitcovski","year":"2017","unstructured":"Pitcovski J, Shahar E, Aizenshtein E, Gorodetsky R. Melanoma antigens and related immunological markers. Crit Rev Oncol Hematol. 2017;115:36\u201349.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4770","key":"6093_CR24","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.3489291","volume":"233","author":"SA Rosenberg","year":"1986","unstructured":"Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233(4770):1318\u201321.","journal-title":"Science"},{"issue":"1","key":"6093_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0022-1759(87)80018-2","volume":"102","author":"SL Topalian","year":"1987","unstructured":"Topalian SL, Muul LM, Solomon D, Rosenberg SA. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods. 1987;102(1):127\u201341.","journal-title":"J Immunol Methods"},{"issue":"6","key":"6093_CR26","first-page":"6421","volume":"14","author":"K Jakubowska","year":"2017","unstructured":"Jakubowska K, Kisielewski W, Ka\u0144czuga-Koda L, Koda M, Famulski W. Stromal and intraepithelial tumor-infiltrating lymphocytes in colorectal carcinoma. Oncol Lett. 2017;14(6):6421\u201332.","journal-title":"Oncol Lett"},{"key":"6093_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-3-030-35723-8_4","volume":"1224","author":"K Iwahori","year":"2020","unstructured":"Iwahori K. Cytotoxic CD8+ lymphocytes in the tumor microenvironment. Adv Exp Med Biol. 2020;1224:53\u201362.","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"6093_CR28","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s43018-023-00521-2","volume":"4","author":"DE Speiser","year":"2023","unstructured":"Speiser DE, Chijioke O, Schaeuble K, M\u00fcnz C. CD4+ T cells in cancer. Nat Cancer. 2023;4(3):317\u201329.","journal-title":"Nat Cancer"},{"issue":"7967","key":"6093_CR29","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41586-023-06199-x","volume":"618","author":"B Kruse","year":"2023","unstructured":"Kruse B, Buzzai AC, Shridhar N, Braun AD, Gellert S, Knauth K, et al. CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours. Nature. 2023;618(7967):1033\u201340.","journal-title":"Nature"},{"issue":"45","key":"6093_CR30","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.1038\/onc.2008.271","volume":"27","author":"TL Whiteside","year":"2008","unstructured":"Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27(45):5904\u201312.","journal-title":"Oncogene"},{"issue":"3","key":"6093_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2023.103404","volume":"71","author":"A Das","year":"2023","unstructured":"Das A, Ghose A, Naicker K, Sanchez E, Chargari C, Rassy E, et al. Advances in adoptive T-cell therapy for metastatic melanoma. Curr Res Transl Med. 2023;71(3): 103404.","journal-title":"Curr Res Transl Med"},{"issue":"11","key":"6093_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013940","volume":"5","author":"LT Nguyen","year":"2010","unstructured":"Nguyen LT, Yen PH, Nie J, Liadis N, Ghazarian D, Al-Habeeb A, et al. Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs). PLoS ONE. 2010;5(11): e13940.","journal-title":"PLoS ONE"},{"issue":"2","key":"6093_CR33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/cgt.2014.81","volume":"22","author":"X Wang","year":"2015","unstructured":"Wang X, Rivi\u00e8re I. Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies. Cancer Gene Ther. 2015;22(2):85\u201394.","journal-title":"Cancer Gene Ther"},{"issue":"15","key":"6093_CR34","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","volume":"86","author":"SA Rosenberg","year":"1994","unstructured":"Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994;86(15):1159\u201366.","journal-title":"J Natl Cancer Inst"},{"issue":"6230","key":"6093_CR35","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","volume":"348","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62\u20138.","journal-title":"Science"},{"key":"6093_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.690499","volume":"12","author":"A Kumar","year":"2021","unstructured":"Kumar A, Watkins R, Vilgelm AE. Cell therapy with TILs: training and taming T cells to fight cancer. Front Immunol. 2021;12: 690499.","journal-title":"Front Immunol"},{"issue":"32","key":"6093_CR37","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","volume":"26","author":"ME Dudley","year":"2008","unstructured":"Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26(32):5233\u20139.","journal-title":"J Clin Oncol"},{"issue":"10","key":"6093_CR38","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","volume":"23","author":"ME Dudley","year":"2005","unstructured":"Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23(10):2346\u201357.","journal-title":"J Clin Oncol"},{"issue":"5","key":"6093_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001743","volume":"9","author":"A Nissani","year":"2021","unstructured":"Nissani A, Lev-Ari S, Meirson T, Jacoby E, Asher N, Ben-Betzalel G, et al. Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy. J Immunother Cancer. 2021;9(5): e001743.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"6093_CR40","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","volume":"17","author":"MB Atkins","year":"1999","unstructured":"Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105\u201316.","journal-title":"J Clin Oncol"},{"issue":"3","key":"6093_CR41","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/imm.13194","volume":"160","author":"AS Chawla","year":"2020","unstructured":"Chawla AS, Khalsa JK, Dhar A, Gupta S, Umar D, Arimbasseri GA, et al. A role for cell-autocrine interleukin-2 in regulatory T-cell homeostasis. Immunology. 2020;160(3):295\u2013309.","journal-title":"Immunology"},{"issue":"13","key":"6093_CR42","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550\u20137.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"6093_CR43","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.21.00612","volume":"39","author":"AA Sarnaik","year":"2021","unstructured":"Sarnaik AA, Hamid O, Khushalani NI, Lewis KD, Medina T, Kluger HM, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J Clin Oncol. 2021;39(24):2656.","journal-title":"J Clin Oncol"},{"issue":"23","key":"6093_CR44","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan MW, Borch TH, van den Berg JH, Met \u00d6, Kessels R, Geukes Foppen MH, et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med. 2022;387(23):2113\u201325.","journal-title":"N Engl J Med"},{"issue":"9","key":"6093_CR45","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1158\/1078-0432.CCR-10-0041","volume":"16","author":"MJ Besser","year":"2010","unstructured":"Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2010;16(9):2646\u201355.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"6093_CR46","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1097\/CJI.0b013e31818403d5","volume":"31","author":"KQ Tran","year":"2008","unstructured":"Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother. 2008;31(8):742\u201351.","journal-title":"J Immunother"},{"issue":"3","key":"6093_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004749","volume":"4","author":"H Wallen","year":"2009","unstructured":"Wallen H, Thompson JA, Reilly JZ, Rodmyre RM, Cao J, Yee C. Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS ONE. 2009;4(3): e4749.","journal-title":"PLoS ONE"},{"issue":"3","key":"6093_CR48","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1158\/1078-0432.CCR-14-1934","volume":"21","author":"JA Chacon","year":"2015","unstructured":"Chacon JA, Sarnaik AA, Chen JQ, Creasy C, Kale C, Robinson J, et al. Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy. Clin Cancer Res. 2015;21(3):611\u201321.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"6093_CR49","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41551-021-00820-y","volume":"6","author":"Z Wang","year":"2022","unstructured":"Wang Z, Ahmed S, Labib M, Wang H, Hu X, Wei J, et al. Efficient recovery of potent tumour-infiltrating lymphocytes through quantitative immunomagnetic cell sorting. Nat Biomed Eng. 2022;6(2):108\u201317.","journal-title":"Nat Biomed Eng"},{"issue":"21","key":"6093_CR50","doi-asserted-by":"publisher","first-page":"15688","DOI":"10.3390\/ijms242115688","volume":"24","author":"AC Uscanga-Palomeque","year":"2023","unstructured":"Uscanga-Palomeque AC, Ch\u00e1vez-Escamilla AK, Alvizo-B\u00e1ez CA, Saavedra-Alonso S, Terrazas-Armend\u00e1riz LD, Tamez-Guerra RS, et al. CAR-T cell therapy: from the shop to cancer therapy. Int J Mol Sci. 2023;24(21):15688.","journal-title":"Int J Mol Sci"},{"issue":"S1","key":"6093_CR51","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.25418","volume":"94","author":"S Feins","year":"2019","unstructured":"Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3\u20139.","journal-title":"Am J Hematol"},{"key":"6093_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103941","volume":"77","author":"D Gumber","year":"2022","unstructured":"Gumber D, Wang LD. Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion. EBioMedicine. 2022;77: 103941.","journal-title":"EBioMedicine"},{"issue":"10","key":"6093_CR53","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1073\/pnas.91.10.4318","volume":"91","author":"D Moritz","year":"1994","unstructured":"Moritz D, Wels W, Mattern J, Groner B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA. 1994;91(10):4318\u201322.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"6093_CR54","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar Z, Waks T, Gkoss G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 1993;90(2):720\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"6093_CR55","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227\u201342.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"6093_CR56","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003354","volume":"9","author":"E Roselli","year":"2021","unstructured":"Roselli E, Boucher JC, Li G, Kotani H, Spitler K, Reid K, et al. 4\u20131BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. J Immunother Cancer. 2021;9(10): e003354.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"6093_CR57","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/sj.leu.2403302","volume":"18","author":"C Imai","year":"2004","unstructured":"Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL, et al. Chimeric receptors with 4\u20131BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004;18(4):676\u201384.","journal-title":"Leukemia"},{"issue":"1","key":"6093_CR58","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","volume":"257","author":"M Chmielewski","year":"2014","unstructured":"Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev. 2014;257(1):83\u201390.","journal-title":"Immunol Rev"},{"issue":"1","key":"6093_CR59","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","volume":"21","author":"A Dimitri","year":"2022","unstructured":"Dimitri A, Herbst F, Fraietta JA. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol Cancer. 2022;21(1):78.","journal-title":"Mol Cancer"},{"issue":"5","key":"6093_CR60","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1158\/0008-5472.CAN-18-3158","volume":"79","author":"EMV Forsberg","year":"2019","unstructured":"Forsberg EMV, Lindberg MF, Jespersen H, Alsen S, Bagge RO, Donia M, et al. HER2 CAR-T cells eradicate uveal melanoma and T-cell therapy-resistant human melanoma in IL2 transgenic NOD\/SCID IL2 receptor knockout mice. Cancer Res. 2019;79(5):899\u2013904.","journal-title":"Cancer Res"},{"issue":"1","key":"6093_CR61","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41408-020-00405-z","volume":"11","author":"AK Mishra","year":"2021","unstructured":"Mishra AK, Kemler I, Dingli D. Preclinical development of CD126 CAR-T cells with broad antitumor activity. Blood Cancer J. 2021;11(1):3.","journal-title":"Blood Cancer J"},{"key":"6093_CR62","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.omto.2020.03.019","volume":"17","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Jiang C, Liu Z, Yang M, Tang X, Wang Y, et al. B7-H3-targeted CAR-T cells exhibit potent antitumor effects on hematologic and solid tumors. Mol Ther Oncolytics. 2020;17:180\u20139.","journal-title":"Mol Ther Oncolytics"},{"issue":"7749","key":"6093_CR63","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","volume":"567","author":"J Chen","year":"2019","unstructured":"Chen J, L\u00f3pez-Moyado IF, Seo H, Lio CWJ, Hempleman LJ, Sekiya T, et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019;567(7749):530\u20134.","journal-title":"Nature"},{"issue":"5","key":"6093_CR64","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1158\/2767-9764.CRC-22-0486","volume":"3","author":"PD Shah","year":"2023","unstructured":"Shah PD, Huang AC, Xu X, Orlowski R, Amaravadi RK, Schuchter LM, et al. Phase I trial of autologous RNA-electroporated cMET-directed CAR T cells administered intravenously in patients with melanoma and breast carcinoma. Cancer Res Commun. 2023;3(5):821\u20139.","journal-title":"Cancer Res Commun"},{"issue":"1","key":"6093_CR65","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/s41467-024-45221-2","volume":"15","author":"S Jilani","year":"2024","unstructured":"Jilani S, Saco JD, Mugarza E, Pujol-Morcillo A, Chokry J, Ng C, et al. CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes. Nat Commun. 2024;15(1):1244.","journal-title":"Nat Commun"},{"issue":"17","key":"6093_CR66","doi-asserted-by":"publisher","first-page":"7622","DOI":"10.7150\/thno.43991","volume":"10","author":"M Yang","year":"2020","unstructured":"Yang M, Tang X, Zhang Z, Gu L, Wei H, Zhao S, et al. Tandem CAR-T cells targeting CD70 and B7\u2013H3 exhibit potent preclinical activity against multiple solid tumors. Theranostics. 2020;10(17):7622\u201334.","journal-title":"Theranostics"},{"issue":"8","key":"6093_CR67","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002151","volume":"9","author":"E Lanitis","year":"2021","unstructured":"Lanitis E, Kosti P, Ronet C, Cribioli E, Rota G, Spill A, et al. VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding. J Immunother Cancer. 2021;9(8): e002151.","journal-title":"J Immunother Cancer"},{"key":"6093_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.835762","volume":"13","author":"P Shafer","year":"2022","unstructured":"Shafer P, Kelly LM, Hoyos V. Cancer therapy with TCR-engineered T cells: current strategies, challenges, and prospects. Front Immunol. 2022;13: 835762.","journal-title":"Front Immunol"},{"issue":"1","key":"6093_CR69","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cell.2020.03.001","volume":"181","author":"EW Weber","year":"2020","unstructured":"Weber EW, Maus MV, Mackall CL. The emerging landscape of immune cell therapies. Cell. 2020;181(1):46\u201362.","journal-title":"Cell"},{"key":"6093_CR70","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/imr.12644","volume":"283","author":"ME Raeber","year":"2018","unstructured":"Raeber ME, Zurbuchen Y, Impellizzieri D, Boyman O. The role of cytokines in T-cell memory in health and disease. Immunol Rev. 2018;283:176\u201393.","journal-title":"Immunol Rev"},{"issue":"6","key":"6093_CR71","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.3390\/cells9061485","volume":"9","author":"JA Rath","year":"2020","unstructured":"Rath JA, Arber C. Engineering strategies to enhance TCR-based adoptive T cell therapy. Cells. 2020;9(6):1485.","journal-title":"Cells"},{"issue":"3","key":"6093_CR72","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1084\/jem.179.3.1005","volume":"179","author":"ABH Bakker","year":"1994","unstructured":"Bakker ABH, Schreurs MWJ, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med. 1994;179(3):1005\u20139.","journal-title":"J Exp Med"},{"issue":"9","key":"6093_CR73","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1073\/pnas.91.9.3515","volume":"91","author":"Y Kawakami","year":"1994","unstructured":"Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA. 1994;91(9):3515\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"6093_CR74","doi-asserted-by":"publisher","first-page":"575","DOI":"10.4049\/jimmunol.169.1.575","volume":"169","author":"S Graff-Dubois","year":"2002","unstructured":"Graff-Dubois S, Faure O, Gross DA, Alves P, Scardino A, Chouaib S, et al. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J Immunol. 2002;169(1):575\u201380.","journal-title":"J Immunol"},{"issue":"1","key":"6093_CR75","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/modpathol.3800232","volume":"18","author":"DA Chitale","year":"2005","unstructured":"Chitale DA, Jungbluth AA, Marshall DS, Leitao MM, Hedvat CV, Kolb D, et al. Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray. Mod Pathol. 2005;18(1):119\u201326.","journal-title":"Mod Pathol"},{"issue":"11","key":"6093_CR76","first-page":"7002","volume":"12","author":"XF Li","year":"2020","unstructured":"Li XF, Ren P, Shen WZ, Jin X, Zhang J. The expression, modulation and use of cancer-testis antigens as potential biomarkers for cancer immunotherapy. Am J Transl Res. 2020;12(11):7002\u201319.","journal-title":"Am J Transl Res"},{"issue":"24","key":"6093_CR77","doi-asserted-by":"publisher","first-page":"9385","DOI":"10.1158\/0008-5472.CAN-09-0494","volume":"69","author":"S Bobisse","year":"2009","unstructured":"Bobisse S, Rondina M, Merlo A, Tisato V, Mandruzzato S, Amendola M, et al. Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors. Cancer Res. 2009;69(24):9385\u201394.","journal-title":"Cancer Res"},{"issue":"5796","key":"6093_CR78","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","volume":"314","author":"RA Morgan","year":"2006","unstructured":"Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126\u20139.","journal-title":"Science"},{"issue":"8","key":"6093_CR79","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/gt.2009.54","volume":"16","author":"PD Peng","year":"2009","unstructured":"Peng PD, Cohen CJ, Yang S, Hsu C, Jones S, Zhao Y, et al. Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. Gene Ther. 2009;16(8):1042\u20139.","journal-title":"Gene Ther"},{"issue":"4","key":"6093_CR80","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/10409238.2017.1304354","volume":"52","author":"M Hudecek","year":"2017","unstructured":"Hudecek M, Izsv\u00e1k Z, Johnen S, Renner M, Thumann G, Ivics Z. Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side. Crit Rev Biochem Mol Biol. 2017;52(4):355\u201380.","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"3","key":"6093_CR81","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1182\/blood-2017-05-787598","volume":"131","author":"M Legut","year":"2018","unstructured":"Legut M, Dolton G, Mian AA, Ottmann OG, Sewell AK. CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells. Blood. 2018;131(3):311\u201322.","journal-title":"Blood"},{"key":"6093_CR82","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/978-1-0716-0290-4_23","volume":"2115","author":"X Zhang","year":"2020","unstructured":"Zhang X, Cheng C, Sun W, Wang H. Engineering T cells using CRISPR\/Cas9 for cancer therapy. Methods Mol Biol. 2020;2115:419\u201333.","journal-title":"Methods Mol Biol"},{"key":"6093_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109055","volume":"110","author":"P Safarzadeh Kozani","year":"2022","unstructured":"Safarzadeh Kozani P, Shokrgozar MA, Evazalipour M, Roudkenar MH. CRISPR\/Cas9-medaited knockout of endogenous T-cell receptor in Jurkat cells and generation of NY-ESO-1-specific T cells: an in vitro study. Int Immunopharmacol. 2022;110: 109055.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"6093_CR84","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","volume":"114","author":"LA Johnson","year":"2009","unstructured":"Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114(3):535\u201346.","journal-title":"Blood"},{"issue":"2","key":"6093_CR85","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1006\/jsre.2001.6148","volume":"98","author":"JS Goydos","year":"2001","unstructured":"Goydos JS, Patel M, Shih W. NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma. J Surg Res. 2001;98(2):76\u201380.","journal-title":"J Surg Res"},{"issue":"3","key":"6093_CR86","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/ijc.2910630313","volume":"63","author":"F Brasseur","year":"1995","unstructured":"Brasseur F, Rimoldi D, Lienard D, Lethe B, Carrel S, Arient F, et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer. 1995;63(3):375\u201380.","journal-title":"Int J Cancer"},{"issue":"7","key":"6093_CR87","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s00403-004-0527-7","volume":"296","author":"C Roeder","year":"2005","unstructured":"Roeder C, Schuler-Thurner B, Berchtold S, Vieth G, Von Den Driesch P, Schuler G, et al. MAGE-A3 is a frequent tumor antigen of metastasized melanoma. Arch Dermatol Res. 2005;296(7):314\u20139.","journal-title":"Arch Dermatol Res"},{"issue":"7","key":"6093_CR88","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","volume":"29","author":"PF Robbins","year":"2011","unstructured":"Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917\u201324.","journal-title":"J Clin Oncol"},{"issue":"2","key":"6093_CR89","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","volume":"36","author":"RA Morgan","year":"2013","unstructured":"Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013;36(2):133\u201351.","journal-title":"J Immunother"},{"issue":"7","key":"6093_CR90","doi-asserted-by":"publisher","first-page":"eadf3700","DOI":"10.1126\/sciadv.adf3700","volume":"9","author":"E Baulu","year":"2023","unstructured":"Baulu E, Gardet C, Chuvin N, Depil S. TCR-engineered T cell therapy in solid tumors: state of the art and perspectives. Sci Adv. 2023;9(7):eadf3700.","journal-title":"Sci Adv"},{"issue":"2","key":"6093_CR91","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1532759","volume":"8","author":"EC Border","year":"2018","unstructured":"Border EC, Sanderson JP, Weissensteiner T, Gerry AB, Pumphrey NJ. Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate. Oncoimmunology. 2018;8(2): e1532759.","journal-title":"Oncoimmunology"},{"issue":"3","key":"6093_CR92","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","volume":"27","author":"NB Nagarsheth","year":"2021","unstructured":"Nagarsheth NB, Norberg SM, Sinkoe AL, Adhikary S, Meyer TJ, Lack JB, et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat Med. 2021;27(3):419\u201325.","journal-title":"Nat Med"},{"issue":"11","key":"6093_CR93","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","volume":"28","author":"J Wagner","year":"2020","unstructured":"Wagner J, Wickman E, DeRenzo C, Gottschalk S. CAR T cell therapy for solid tumors: bright future or dark reality? Mol Ther. 2020;28(11):2320\u201339.","journal-title":"Mol Ther"},{"issue":"11","key":"6093_CR94","doi-asserted-by":"publisher","first-page":"e816","DOI":"10.1016\/S2352-3026(20)30277-5","volume":"7","author":"T Anagnostou","year":"2020","unstructured":"Anagnostou T, Riaz IB, Hashmi SK, Murad MH, Kenderian SS. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis. Lancet Haematol. 2020;7(11):e816\u201326.","journal-title":"Lancet Haematol"},{"issue":"3","key":"6093_CR95","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21(3):145\u201361.","journal-title":"Nat Rev Cancer"},{"key":"6093_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.795164","volume":"13","author":"P Safarzadeh Kozani","year":"2022","unstructured":"Safarzadeh Kozani P, Safarzadeh Kozani P, Ahmadi Najafabadi M, Yousefi F, Mirarefin SMJ, Rahbarizadeh F. Recent advances in solid tumor CAR-T cell therapy: driving tumor cells from hero to zero? Front Immunol. 2022;13: 795164.","journal-title":"Front Immunol"},{"issue":"3","key":"6093_CR97","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19(3):200\u201318.","journal-title":"Nat Rev Drug Discov"},{"key":"6093_CR98","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","volume":"9","author":"AM Abel","year":"2018","unstructured":"Abel AM, Yang C, Thakar MS, Malarkannan S. Natural killer cells: development, maturation, and clinical utilization. Front Immunol. 2018;9:1869.","journal-title":"Front Immunol"},{"issue":"8","key":"6093_CR99","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051\u20137.","journal-title":"Blood"},{"issue":"5562","key":"6093_CR100","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097\u2013100.","journal-title":"Science"},{"issue":"6","key":"6093_CR101","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545\u201353.","journal-title":"N Engl J Med"},{"issue":"15","key":"6093_CR102","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.3390\/cancers14153839","volume":"14","author":"M Sabbah","year":"2022","unstructured":"Sabbah M, Jondreville L, Lacan C, Norol F, Vieillard V, Roos-Weil D, et al. CAR-NK cells: a chimeric hope or a promising therapy? Cancers. 2022;14(15):3839.","journal-title":"Cancers"},{"issue":"11","key":"6093_CR103","doi-asserted-by":"publisher","first-page":"5899","DOI":"10.3390\/ijms22115899","volume":"22","author":"E Wrona","year":"2021","unstructured":"Wrona E, Borowiec M, Potemski P. CAR-NK cells in the treatment of solid tumors. Int J Mol Sci. 2021;22(11):5899.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"6093_CR104","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32(2):520\u201331.","journal-title":"Leukemia"},{"issue":"5","key":"6093_CR105","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood.2020007748","volume":"137","author":"M Daher","year":"2021","unstructured":"Daher M, Basar R, Gokdemir E, Baran N, Uprety N, Nunez Cortes AK, et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood. 2021;137(5):624.","journal-title":"Blood"},{"issue":"7","key":"6093_CR106","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.it.2013.03.002","volume":"34","author":"SQ Crome","year":"2013","unstructured":"Crome SQ, Lang PA, Lang KS, Ohashi PS. Natural killer cells regulate diverse T cell responses. Trends Immunol. 2013;34(7):342\u20139.","journal-title":"Trends Immunol"},{"issue":"2","key":"6093_CR107","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1073\/pnas.1012356108","volume":"108","author":"A De Maria","year":"2011","unstructured":"De Maria A, Bozzano F, Cantoni C, Moretta L. Revisiting human natural killer cell subset function revealed cytolytic CD56dimCD16+ NK cells as rapid producers of abundant IFN-\u03b3 on activation. Proc Natl Acad Sci USA. 2011;108(2):728\u201332.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"6093_CR108","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1365-2567.2008.03027.x","volume":"126","author":"A Poli","year":"2009","unstructured":"Poli A, Michel T, Th\u00e9r\u00e9sine M, Andr\u00e8s E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126(4):458\u201365.","journal-title":"Immunology"},{"issue":"1","key":"6093_CR109","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1038\/s41598-019-40933-8","volume":"9","author":"K de Jonge","year":"2019","unstructured":"de Jonge K, Ebering A, Nassiri S, Maby-El Hajjami H, Ouertatani-Sakouhi H, Baumgaertner P, et al. Circulating CD56bright NK cells inversely correlate with survival of melanoma patients. Sci Rep. 2019;9(1):4487.","journal-title":"Sci Rep"},{"key":"6093_CR110","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/ncomms6639","volume":"5","author":"TH Ali","year":"2014","unstructured":"Ali TH, Pisanti S, Ciaglia E, Mortarini R, Anichini A, Garofalo C, et al. Enrichment of CD56dimKIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. Nat Commun. 2014;5:639.","journal-title":"Nat Commun"},{"issue":"6","key":"6093_CR111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13061363","volume":"13","author":"H Lee","year":"2021","unstructured":"Lee H, Da Silva IP, Palendira U, Scolyer RA, Long GV, Wilmott JS. Targeting NK cells to enhance melanoma response to immunotherapies. Cancers. 2021;13(6):1\u201330.","journal-title":"Cancers"},{"key":"6093_CR112","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.3389\/fonc.2019.01529","volume":"9","author":"MS Thakar","year":"2020","unstructured":"Thakar MS, Kearl TJ, Malarkannan S. Controlling cytokine release syndrome to harness the full potential of car-based cellular therapy. Front Oncol. 2020;9:1529.","journal-title":"Front Oncol"},{"key":"6093_CR113","doi-asserted-by":"publisher","first-page":"1212546","DOI":"10.3389\/fimmu.2023.1212546","volume":"14","author":"C Gouttefangeas","year":"2023","unstructured":"Gouttefangeas C, Klein R, Maia A. The good and the bad of T cell cross-reactivity: challenges and opportunities for novel therapeutics in autoimmunity and cancer. Front Immunol. 2023;14:1212546.","journal-title":"Front Immunol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06093-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06093-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06093-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T10:04:04Z","timestamp":1737540244000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06093-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":113,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6093"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06093-2","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review article does not involve any human or animal experiments, and thus ethics approval and consent to participate are not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}